Citigroup Inc Red Hill Biopharma Ltd. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.14 - $695.9 $5 - $27,836	40 Added 4.01%	1,038 $0
Q3 2022 Nov 10, 2022	SELL	$0.5 - $523.8 $1,936 - $2.03 Million	-3,873 Reduced 79.51%	998 $1,000
Q2 2022 Aug 10, 2022	BUY	$0.63 - $2.58 $2,353 - $9,638	3,736 Added 329.16%	4,871 $4,000
Q1 2022 May 12, 2022	SELL	$1.65 - $3.12 $483 - $914	-293 Reduced 20.52%	1,135 $3,000
Q4 2021 Feb 10, 2022	SELL	$2.31 - $5.85 $2,353 - $5,961	-1,019 Reduced 41.64%	1,428 $4,000
Q3 2021 Nov 10, 2021	BUY	$4.55 - $10.36 $11,133 - $25,350	2,447 New	2,447 $11,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.